Analysis of antibiotic resistant infections associated with hirudotherapy
Research article published in American journal of otolaryngology (2024)
Abstract
OBJECTIVE: Given rising concern regarding antibiotic resistance, our objective was to evaluate antibiotic-resistant infections following leech therapy and to characterize the use of prophylactic antibiotics. METHODS: All reports of adverse events involving hirudotherapy (product code "NRN") were retrieved from the U.S. Food and Drug Administration MAUDE database between 2012 and 2021. Antibiotic resistance was defined by bacterial culture or infection after antibiotic administration. RESULTS: Nineteen cases of antibiotic resistance involving hirudotherapy were identified. Only three cases of antibiotic resistance were discovered on routine testing and the remaining 16 cases were associated with patient injury. Positive blood cultures or fever were present in 26.3 % (n = 5) of cases. Cultures of the infection grew Aeromonas hydrophilia (n = 13; 68.4 %), Vibrio vulnificus (n = 3; 15.8 %), Pseudomonas aeruginosa (n = 2; 10.5 %), and Proteus vulgaris (n = 1; 5.3 %). There were nine (47.4 %) multi-drug resistant infections. Infection was most commonly resistant to fluoroquinolones (n = 9; 47.4 %), trimethoprim-sulfamethoxazole (n = 9; 47.4 %) and ertapenem (n = 4; 21.1 %). CONCLUSION: Antibiotic-resistant infections involving hirudotherapy are frequently resistant to multiple drugs, including fluoroquinolones and trimethoprim-sulfamethoxazole. Resistance to ertapenem, a drug of last resort, was also documented. The findings presented in this study support growing literature that the trend in multi-drug resistance is more severe than previously reported.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Given rising concern regarding antibiotic resistance, our objective was to evaluate antibiotic-resistant infections following leech therapy and to characterize the use of prophylactic antibiotics.
Por qué esto importa para la hirudoterapia
Este estudio analizó los informes de eventos adversos de la base de datos MAUDE de la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA) (2012–2021) para evaluar las infecciones resistentes a los antibióticos posteriores a la terapia con sanguijuelas y caracterizar el uso profiláctico de antibióticos, identificando 19 casos de resistencia con infecciones causadas por Aeromonas hydrophila, Vibrio vulnificus, Pseudomonas aeruginosa y Proteus vulgaris. Estos hallazgos son directamente relevantes para la seguridad de la hirudoterapia, ya que documentan resistencia a múltiples fármacos—incluyendo la resistencia a ertapenem, descrito en el resumen como un fármaco de último recurso—en infecciones bacterianas asociadas con el uso de sanguijuelas medicinales. El análisis se limita a 19 casos recuperados de un sistema de notificación de eventos adversos, y el resumen no proporciona datos de denominador ni tasas de incidencia para cuantificar el riesgo global de infección. Este estudio plantea una señal de seguridad importante para los profesionales, pero no puede establecer la prevalencia de resistencia a nivel poblacional asociada con la hirudoterapia.
Citación
Analysis of antibiotic resistant infections associated with hirudotherapy.
Brauer P et al. · American journal of otolaryngology, 2024
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: March 18, 2026 · Última actualización del sitio: June 18, 2026